سامانه مدیریت نشریات علمی دانشگاه علوم پزشکی مشهد

Sahebari, Maryam, Mirfeizi, Zahra, Hashemzadeh, Kamila, Salavati Nik, Ensie, Gholampoor Shamkani, Negar. (1401). Effects of Biologic Therapies on the Chance of COVID-19 Infection Among Rheumatoid Arthritis and Lupus Patients During the First Wave of the Pandemic. , 10(11), 946-968. doi: 10.22038/abjs.2022.60064.2959
Maryam Sahebari; Zahra Mirfeizi; Kamila Hashemzadeh; Ensie Salavati Nik; Negar Gholampoor Shamkani. "Effects of Biologic Therapies on the Chance of COVID-19 Infection Among Rheumatoid Arthritis and Lupus Patients During the First Wave of the Pandemic". , 10, 11, 1401, 946-968. doi: 10.22038/abjs.2022.60064.2959
Sahebari, Maryam, Mirfeizi, Zahra, Hashemzadeh, Kamila, Salavati Nik, Ensie, Gholampoor Shamkani, Negar. (1401). 'Effects of Biologic Therapies on the Chance of COVID-19 Infection Among Rheumatoid Arthritis and Lupus Patients During the First Wave of the Pandemic', , 10(11), pp. 946-968. doi: 10.22038/abjs.2022.60064.2959
Sahebari, Maryam, Mirfeizi, Zahra, Hashemzadeh, Kamila, Salavati Nik, Ensie, Gholampoor Shamkani, Negar. Effects of Biologic Therapies on the Chance of COVID-19 Infection Among Rheumatoid Arthritis and Lupus Patients During the First Wave of the Pandemic. , 1401; 10(11): 946-968. doi: 10.22038/abjs.2022.60064.2959

Effects of Biologic Therapies on the Chance of COVID-19 Infection Among Rheumatoid Arthritis and Lupus Patients During the First Wave of the Pandemic

The Archives of Bone and Joint Surgery
مقاله 5، دوره 10، شماره 11، بهمن 2022، صفحه 946-968    اصل مقاله (437.78 K)
نوع مقاله: RESEARCH PAPER
شناسه دیجیتال (DOI): 10.22038/abjs.2022.60064.2959
نویسندگان
Maryam Sahebari1؛ Zahra Mirfeizi* 1؛ Kamila Hashemzadeh1؛ Ensie Salavati Nik2؛ Negar Gholampoor Shamkani2
1Rheumatic Diseases Research Center (RDRC), Mashhad Universality of Medical Sciences, Mashhad, Iran
2Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
چکیده
risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Despite the effectiveness of using
combined conventional and biological disease-modifying anti-rheumatic drugs(bDMARDs) in managing rheumatic
diseases, there have been concerns that taking biological agents may have an additive effect on getting infected with
COVID-19. This study evaluates the impact of taking biological agents on altering the chance of getting infected with
SARS-CoV-2 in rheumatoloid and lupus patients compared to traditional DMARDs.
Methods: We carried out a cross-sectional survey study from February 2020 to January 2021 on patients diagnosed
with lupus and rheumatid arthritis. COVID-19 infection was confirmed by the presence of symptoms and signs of the disease
and para-clinical findings such as lymphopenia and elevated C-reactive protein (CRP) and positive chest CT scan
or polymerase chain reaction (PCR) of COVID-19.
Results: Out of 591 patients included in this study, 422 (71.4%) had rheumatoid arthritis (RA), and 169 (28.6%) had
systemic lupus erythematosus (SLE). Among them, 56 (9.5%) cases were diagnosed with COVID-19 infection. No
association was found between age, gender, or type of rheumatological diseases and SARS-CoV-2. There was a
significant association between COVID-19 infection and treatment with biological drugs (P-value<0.05) regardless of
the type of rheumatologic disease. Interestingly, the analysis revealed that the type of biologic drug also altered the
chance of COVID-19 infection; In fact, patients who took TNF inhibitors were significantly at a higher risk of disease
than those taking Rituximab (P-value=0.000). Identical results were observed among RA patients (P-value<0.001),
however, all 5 (3%) lupus cases treated with Rituximab infected with covid 19.
Conclusion: This study develops a better understanding of the risk of immunosuppressive medications for SARSCoV-
2 infection. Patients treated with conventional and biological medicine had a higher disease risk than those taking
exclusively conventional drugs. However, more studies are required to deliberate the relation of the reviewed factors
with the severity of COVID-19.
Level of evidence: II
کلیدواژه‌ها
Anti-TNFs؛ Biological DMARDs؛ COVID-19؛ Adalimumab؛ Infliximab؛ Rituximab؛ Rheumatoid arthritis (RA)؛ Systemic lupus erythematous (SLE)؛ Altebrel؛ CinnoRA
مراجع
  1. Montero F, Martínez-Barrio J, Serrano-Benavente B, et al. Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes. Rheumatol Int.2020;40(10):1593-8. doi: 10.1007/s00296-020-04676-4
  2. Liu Y, Sawalha AH, Lu Q. COVID-19 and autoimmune diseases. Curr Opin Rheumatol. 2021;33(2):155-62. doi: 10.1097/BOR.0000000000000776.
  3. Panjavi B, Kamrani RS, Ghane B. The Ups and Downs of COVID-19 Epidemics for Orthopedic Community. Arch Bone Jt Surg. 2020;8(Supplement 1):218-9. doi: 10.22038/abjs.2020.47734.2343.
  4. Goldblatt F, Chambers S, Rahman A, Isenberg D. Serious infections in British patients with systemic lupus erythematosus: hospitalisations and mortality. Lupus. 2009;18(8):682-9doi: 10.1177/0961203308101019.
  5. Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology. 2012; 52(1):53-61. doi: 10.1093/rheumatology/kes305.
  6. Favalli EG, Agape E, Caporali R. Incidence and Clinical Course of COVID-19 in Patients with Connective Tissue Diseases: A Descriptive Observational Analysis. J Rheumatol. 2020;47(8):1296. doi: 10.3899/jrheum.200507.
  7. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430-6. doi: 10.1038/s41586-020-2521-4.
  8. Migkos MP, Kaltsonoudis E, Pelechas E, et al. Use of conventional synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatic diseases contracting COVID-19: a single-center experience. Rheumatol Int. 2021;41(5):903-9. doi: 10.1007/s00296-021-04818-2.
  9. Michelena X, Borrell H, López-Corbeto M, et al. Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum. 2020;50(4):564-70. doi: 10.1016/j.semarthrit.2020.05.001.
  10. Dejaco C, Alunno A, Bijlsma JW, et al. Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries. Ann Rheum Dis. 2021;80(4):518-26. doi: 10.1136/annrheumdis-2020-218697.
  11. Price E, MacPhie E, Kay L, et al. Identifying rheumatic disease patients at high risk and requiring shielding during the COVID-19 pandemic. Clin Med (Lond). 2020;20(3):256-61. doi: 10.7861/clinmed.2020-0149.
  12. Quartuccio L, Valent F, Pasut E, Tascini C, De Vita S. Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: A population-based study in the first two months of COVID-19 outbreak in Italy. Joint Bone Spine. 2020;87(5):439-43. doi: 10.1016/j.jbspin.2020.05.003.
  13. Schoot TS, Kerckhoffs APM, Hilbrands LB, van Marum RJ. Immunosuppressive Drugs and COVID-19: A Review. Front Pharmacol. 2020;11: 1333. doi: 10.3389/fphar.2020.01333.
  14. Calabrese C. COVID-19 and your rheumatology patients. Cleve Clin J Med. 2020. doi: 10.3949/ccjm.87a.ccc027.
  15. Sanchez-Piedra C, Diaz-Torne C, Manero J, et al. Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. Ann Rheum Dis. 2020;79(7):988-90. doi: 10.1136/annrheumdis-2020-217948.
  16. Freites Nuñez DD, Leon L, Mucientes A, et al. Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(11):1393-9. doi: 10.1136/annrheumdis-2020-217984.
  17. Bachiller-Corral J, Boteanu A, Garcia-Villanueva MJ, et al. Risk of Severe COVID-19 Infection in Patients With Inflammatory Rheumatic Diseases. J Rheumatol. 2021;48(7):1098-102. doi: 10.3899/jrheum.200755.
  18. Santos CS, Férnandez XC, Moriano Morales C, et al. Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe? RMD Open. 2021;7(1):e001439. doi: 10.1136/rmdopen-2020-001439.
  19. Mahmoudi S, Mehdizadeh M, Shervin Badv R, et al. The Coronavirus Disease 2019 (COVID-19) in Children: A Study in an Iranian Children’s Referral Hospital. Infect Drug Resist. 2020;13:2649-55. doi: 10.2147/IDR.S259064.
  20. Salehi-Abari I, Khazaeli S, Salehi-Abari F, Salehi-Abari A. Practical Guideline for Screening the Patients with SARS-CoV-2 Infection and Persian Gulf Criteria for Diagnosis of COVID-19. Advances in Infectious Diseases. 2020;10(03):67. DOI:10.4236/aid.2020.103008
آمار
تعداد مشاهده مقاله: 471
تعداد دریافت فایل اصل مقاله: 387